Korean J Schizophr Res.  2024 Oct;27(2):29-34. 10.16946/kjsr.2024.27.2.29.

Atypical Antipsychotics Use and Neuroleptic Malignant Syndrome: A Review With a Clinical Perspective

• Kim K

• KMID: 2560352
• DOI: http://doi.org/10.16946/kjsr.2024.27.2.29

Abstract

Neuroleptic malignant syndrome (NMS) is a potentially life-threatening idiosyncratic reaction associated with the use of antipsychotic medications, characterized by hyperthermia, muscle rigidity, and alterations in consciousness. Despite a reduction in its incidence due to the predominance of atypical antipsychotics in contemporary treatment regimens, NMS remains a critical neuropsychiatric emergency that warrants vigilant attention. There is a hypothesis proposing that catatonia and NMS may exist along a continuum of the same disorder, and evidence suggests that lorazepam may offer therapeutic benefits for both conditions. It is potential for the concurrent occurrence of NMS and serotonin syndrome when antipsychotics and antidepressants are administered concomitantly. This paper presents a case of NMS following the reinitiation of antipsychotic treatment over an extended duration, a scenario inadequately addressed in existing reports, and discusses strategies for its management in clinical practice.

Keyword

Atypical antipsychotics; Catatonia; Lorazepam; Neuroleptic malignant syndrome; Serotonin syndrome; 긴장증; 로라제팜; 비정형 항정신병약물; 세로토닌 증후군; 신경이완제 악성 증후군

Reference

1. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A. 2000; 97:7673–7675.

2. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998; 49:1163–1172.

3. Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004; 37(Suppl 1):S54–S64.

4. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007; 164:870–876.

5. Spivak B, Maline DI, Vered Y, Kozyrev VN, Mester R, Neduva SA, et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2000; 102:226–230.

6. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004; 65:464–470.

7. Szota AM, Radajewska I, Araszkiewicz AS. Atypical neuroleptic malignant syndrome: case reports and diagnostic challenges. J Psychoactive Drugs. 2022; 54:284–293.

8. Kwak YT, Koo MS. [Olanzapine-induced neuroletpic malignant syndrome]. J Korean Neurol Assoc. 2000; 18:249–251. Korean.

9. Khaldi S, Kornreich C, Choubani Z, Gourevitch R. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review]. Encephale. 2008; 34:618–624. French.

10. Zhao H, Lu S, Li X, Huang P, Wang H, Lu F. Multidisciplinary collaboration in diagnosis and treatment of neuroleptic malignant syndrome complicated with pneumonia: report of three cases. Diagn Pathol. 2022; 17:89.

11. Ozaal S, Katulanda G. Exceptionally high creatine kinase levels in risperidone-induced neuroleptic malignant syndrome: a case report. SAGE Open Med Case Rep. 2022; 10:2050313X221085096.

12. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998; 155:1113–1116.

13. Castelijns MH, Keeris LM, van der Hoeven JH. Risperidone-induced severe rhabdomyolysis: a case report. Clin Case Rep Rev. 2016; 2:1000241.

14. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG. Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26:897–902.

15. Guinart D, Misawa F, Rubio JM, Pereira J, de Filippis R, Gastaldon C, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021; 144:329–341.

16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association Publishing;2022.

17. Funayama M, Takata T, Koreki A, Ogino S, Mimura M. Catatonic stupor in schizophrenic disorders and subsequent medical complications and mortality. Psychosom Med. 2018; 80:370–376.

18. Oldham MA. The probability that catatonia in the hospital has a medical cause and the relative proportions of its causes: a systematic review. Psychosomatics. 2018; 59:333–340.

19. White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991; 158:419–421.

20. Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30:1182–1183.

21. Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023; 37:327–369.

22. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm (Vienna). 2002; 109:1453–1467.

23. Northoff G, Kötter R, Baumgart F, Danos P, Boeker H, Kaulisch T, et al. Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. Schizophr Bull. 2004; 30:405–427.

24. Rodriguez S, Dufendach KA, Weinreib RM. Neuroleptic malignant syndrome or catatonia? A case report. J Crit Care Med (Targu Mures). 2020; 6:190–193.

25. Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry. 1997; 62:404–406.

26. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239–245.

27. World Health Organization, Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [Internet]. Geneva: World Health Organization;2018. [cited 2024 Jun 14]. Available from: http://www.who-umc.org/Graphics/24734.pdf.

28. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85:129–135.

29. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112–1120.

30. Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of serotonin syndrome with neuroleptic malignant syndrome due to linezolid-fluoxetine and olanzapine-metoclopramide interactions: a case report of two serious adverse drug effects caused by medication reconciliation failure on hospital admission. Case Rep Med. 2016; 2016:7128909.

31. Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: a case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015; 18:100–101.

32. Richter A, Grimm S, Northoff G. Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia. Hum Psychopharmacol. 2010; 25:55–62.

33. Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother. 2016; 50:973–981.

34. Ross C. Successful clozapine rechallenge following clozapine-induced neuroleptic malignant syndrome. Mental Health Clinician. 2015; 5:88–90.

35. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016; 24:97–103.